DEF 14A: Teladoc Health Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Teladoc Health's upcoming annual meeting will address director elections, executive compensation, auditor ratification, and other corporate matters.

Summary

• Teladoc Health will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024.
• Stockholders of record as of March 28, 2024, are eligible to vote.
• The meeting will cover the election of eight director nominees, an advisory vote on executive compensation (Say-on-Pay), an advisory vote on the frequency of future Say-on-Pay votes, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2024.
• The Board recommends voting FOR each director nominee, FOR the Say-on-Pay proposal, for a 1 YEAR frequency for future Say-on-Pay votes, and FOR the ratification of Ernst & Young LLP.
• In 2023, Teladoc Health reported revenue growth of 8% to $2.6 billion, adjusted EBITDA growth of 33% to $328 million, and free cash flow of $194 million.
• The company is focused on human capital management, diversity, equity, and inclusion, and community impact, including volunteering over 13,000 hours globally in 2023.
• Teladoc Health's executive compensation program aims to align executive pay with corporate performance and stockholder interests, with long-term incentives making up a significant portion of executive compensation.
• The Compensation Committee has adjusted the compensation program to emphasize long-term performance periods for performance-based restricted stock units and reduce the burn rate.
• The Board has adopted an Incentive-Based Compensation Recovery Policy (clawback policy) that complies with SEC rules and NYSE listing standards.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights positive financial results and corporate initiatives, it also acknowledges a decline in Say-on-Pay support and falling short of performance goals. The overall tone is cautiously optimistic.

Positives

• Teladoc Health achieved significant revenue and adjusted EBITDA growth in 2023.
• The company is committed to human capital management, diversity, equity, and inclusion.
• Teladoc Health actively engages in community impact initiatives.
• The executive compensation program is designed to align executive pay with corporate performance and stockholder interests.
• The company has a clawback policy in place.

Negatives

• The Say-on-Pay vote received a lower percentage of votes in favor in 2023 (81.9%) compared to 2022 (91.6%) and 2021 (87.2%).
• The company's performance fell just short of its rigorous goals.

Risks

• Changes in laws and regulations applicable to the business model.
• Changes in market conditions and receptivity to services and offerings.
• Potential loss of key clients or a significant number of members or BetterHelp paying users.
• Changes in valuations or useful lives of assets.
• Changes to abilities to recruit and retain qualified providers into the network.
• Impact of and risk related to impairment losses with respect to goodwill or other assets.
• Success of the operational review of the Company to achieve a more balanced approach to growth and margin.

Future Outlook

The company aims to continue driving growth and profitability while focusing on human capital management, diversity, equity, and inclusion, and community impact.

Industry Context

Teladoc Health continues to be a leader in whole-person virtual care, operating in an increasingly competitive environment.

Management Changes

Related Party Transactions

• In 2023, Teladoc Health entered into a contract with Cedar Gate Technologies for data and value-based analytics tools, with Mr. Snow, the Chairman of the Board, being the Chief Executive Officer at Cedar Gate and owning approximately 10% of its outstanding capital stock.
• Pursuant to this contract, Teladoc Health will pay approximately $6.3 million to Cedar Gate over the three-year term, which includes an option for Teladoc Health to terminate after one year.

Stakeholder Impact

• The proposals outlined in the proxy statement will impact stockholders through their voting rights and influence on corporate governance.
• Executive compensation decisions impact executives and employees.
• The company's performance and initiatives affect customers, partners, and the broader healthcare community.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The Board and Compensation Committee will consider the outcome of the advisory votes when making future decisions.

Key Dates

Keywords

proxy statement, executive compensation, annual meeting, corporate governance, director nominees, Teladoc Health, stockholders, audit, EBITDA, revenue